Tag Archive for: Phase 2a trial

Poolbeg Pharma announces successful site activation for POLB 001 TOPICAL clinical trial

/in

Major operational milestone achieved with interim data on track for summer 2026 11 June 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the first site activation for the first-in-patient POLB 001 TOPICAL* clinical trial has occurred. This follows the successful completion of […]

Read more

Poolbeg Pharma plc – Interim Results for the six months to 30 June 2025

/in

Well-funded with multiple upcoming clinical milestones 29 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2025. Read more…

Read more

Poolbeg Pharma plc – ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost

/in

Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres  25 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (“ACT”), to […]

Read more
© Optimum Strategic Communications.